Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.30 USD
Change Today +0.23 / 1.35%
Volume 323.0K
As of 8:10 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

sucampo pharmaceuticals-cl a (SCMP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/15 - $22.00
52 Week Low
07/31/14 - $5.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sucampo pharmaceuticals-cl a (SCMP) Related Businessweek News

No Related Businessweek News Found

sucampo pharmaceuticals-cl a (SCMP) Details

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, as well as other therapeutic applications of drug technologies. The company’s product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

80 Employees
Last Reported Date: 03/9/15
Founded in 1996

sucampo pharmaceuticals-cl a (SCMP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $440.2K
Co-Founder, Chairman Emeritus and Scientific ...
Total Annual Compensation: $144.5K
Chief Financial Officer
Total Annual Compensation: $286.0K
Senior Vice President of Sales & Marketing an...
Total Annual Compensation: $242.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $338.9K
Compensation as of Fiscal Year 2014.

sucampo pharmaceuticals-cl a (SCMP) Key Developments

Sucampo Pharmaceuticals, Inc. Accepts Investigational New Drug Application for A Pivotal Study of AMITIZA

Sucampo Pharmaceuticals, Inc. announced that the China Food and Drug Administration (CFDA) has accepted an Investigational New Drug (IND) application for a pivotal study of AMITIZA in patients with chronic idiopathic constipation. Harbin Gloria Pharmaceuticals Co. Ltd. (Gloria) will design and conduct the study under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for AMITIZA in China. In connection with the IND acceptance, Sucampo will receive $500,000 from Gloria, which is the second tranche of the $1.5 million upfront payment agreed to as part of the licensing agreement.

Sucampo Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:00 PM

Sucampo Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Sucampo Pharmaceuticals and Harbin Gloria Pharmaceuticals Co Announce AMITIZA (Lubiprostone) Partnership in China

Sucampo Pharmaceuticals revealed the execution of an exclusive license, development, commercialization and supply agreement for AMITIZA (lubiprostone) in China in partnership with Harbin Gloria Pharmaceuticals Co. This agreement provides Gloria with the rights to develop and commercialize Sucampo's AMITIZA in China, subject to regulatory approval of the product by the China Food and Drug dministration (CFDA). Under the terms of the agreement, Sucampo will receive an upfront payment of USD 1.5 million. The upfront payment will consist of USD 1 million within 30 days of signing the agreement and USD 500,000 within 30 days of investigational new drug application approval in China. In conjunction, Sucampo will be eligible for an additional milestone payment upon the occurrence of a regulatory or alternatively a commercial milestone event. It will be the exclusive supplier of AMITIZA to Gloria at an agreed-upon supply price. The term of this agreement is 13 years with renewal terms. Additionally, Gloria will be responsible for all development activities and costs as well as all commercialization and regulatory activities in China.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCMP:US $17.30 USD +0.23

SCMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $7.23 USD -0.17
Momenta Pharmaceuticals Inc $21.61 USD -0.13
Pernix Therapeutics Holdings Inc $5.63 USD -0.22
Progenics Pharmaceuticals Inc $7.30 USD +0.23
Sagent Pharmaceuticals Inc $26.06 USD +0.37
View Industry Companies

Industry Analysis


Industry Average

Valuation SCMP Industry Range
Price/Earnings 40.8x
Price/Sales 6.3x
Price/Book 8.1x
Price/Cash Flow 41.0x
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUCAMPO PHARMACEUTICALS-CL A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at